FDA Approves and Launches Priovant's Oral Dermatomyositis Therapy Lisraya in the U.S.
First Targeted Oral Therapy
The U.S. Food and Drug Administration (FDA) approved Lisraya (brepoxitinib) from Priovant Therapeutics on August 27, 2026, for the treatment of adult patients with dermatomyositis. Lisraya is a once-daily 30mg tablet that inhibits tyrosine kinase 2 and Janus kinase 1 (TYK2/JAK1), thereby blocking signals from interferons 1 and 2 and interleukins (IL)-6, -12, and -23. This is the first FDA-approved oral therapy and the first targeted therapy for dermatomyositis, with U.S. supply beginning immediately after approval. The decision followed rare disease designation and priority review, marking a regulatory milestone that shifts treatment pathways from steroid- and non-specific immunosuppressant-based approaches.
Disease Improvement and Steroid Reduction Proven in Phase 3
The approval was based on the Phase 3 VALOR study (NCT05437263), which evaluated 241 adults randomized 1:1:1 to brepoxitinib 30mg, 15mg, or placebo over 52 weeks. The 30mg dose, the approved regimen, showed a mean 15.3-point improvement in Total Improvement Score (TIS) over placebo with statistical significance of p<0.001, and all nine key secondary endpoints were met. The proportion achieving moderate or greater TIS improvement along with minimal dose or steroid-free status was 55% versus 30%, and the proportion achieving complete steroid discontinuation in patients with baseline steroids ≥7.5mg was 45% versus 29%. However, a boxed warning was applied due to risks of serious infections and related events, including serious infections, death, malignancies, major cardiovascular events, and thrombosis.
Octagam and Later-Stage Pipeline Pose Competitive Pressure
The previously FDA-approved therapy for dermatomyositis is Octagam 10% (intravenous human immunoglobulin G) from Octapharma AG, which received approval in July 2021. In clinical practice, corticosteroids combined with immunosuppressants such as methotrexate, azathioprine, and mycophenolate have been standard, but long-term toxicity and non-specific immunosuppression have been burdensome. Lisraya is targeting the intravenous-dominant market with its oral convenience and steroid-reduction data, but Pfizer's (PFE) anti-interferon-beta antibody dakilimab and AstraZeneca's (AZN) anti-interferon receptor antibody anifrolumab are in Phase 3 and pose competitive threats. Therefore, early market penetration will depend on insurance coverage and the ability to select patients who are eligible for the boxed warning.
Roivant's First Commercial Asset Realized
Priovant was established in 2021 through a collaboration between Roivant Sciences (ROIV) and Pfizer, with Roivant holding 74% and Pfizer 25%. Priovant holds commercial rights in the U.S. and Japan, while Pfizer holds rights in the rest of the world, with the initial agreement including a USD 10 million upfront payment including inventory. If annual net sales in the U.S. and Japan exceed mid-billion dollars, Priovant will pay Pfizer mid-hundreds of millions in sales milestones and low-teen percentages in tiered royalties. The global dermatomyositis market is projected to grow from USD 637.7 million in 2026 to USD 931.6 million in 2033, making this approval a key event for Roivant to convert its clinical assets into revenue-generating products.
Lisraya is an approved and marketed asset that demonstrated a 15.3-point improvement in 52-week TIS over placebo with p<0.001 in the Phase 3 VALOR trial, creating a new revenue base for Roivant. In the USD 637.7 million global dermatomyositis market in 2026, the once-daily oral dosing and 45% complete steroid discontinuation rate differentiate Lisraya from Octapharma's intravenous Octagam 10% and traditional immunosuppressants. While long-term competition from Pfizer's Phase 3 dakilimab and AstraZeneca's Phase 3 anifrolumab may intensify, Lisraya has secured a first-mover advantage as the first targeted oral therapy. From a research and business development perspective, the clinical validity of TYK2/JAK1 dual inhibition is established, but the boxed warning and risk of serious infections remain key constraints for prescription expansion and insurance negotiations.